

Joseph L Izzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4105376/publications.pdf>

Version: 2024-02-01

45
papers

20,056
citations

567144

15
h-index

330025

37
g-index

45
all docs

45
docs citations

45
times ranked

17550
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study. <i>Circulation: Heart Failure</i> , 2021, 14, e007891.	1.6	6
2	Cardiovascular Health in a Single Community in Rural Haiti: A Cross-sectional Study. <i>Caribbean Medical Journal</i> , 2021, 83, .	0.1	0
3	Pitfalls of Pulse Wave Analysis and Oscillometric Blood Pressure Derivatives. <i>Hypertension</i> , 2021, 78, 372-375.	1.3	5
4	Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1183-1190.	1.0	6
5	Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1077.	3.8	220
6	Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy. <i>Journal of Clinical Hypertension</i> , 2019, 21, 922-928.	1.0	6
7	Pulse Wave Velocities Derived From Cuff Ambulatory Pulse Wave Analysis. <i>Hypertension</i> , 2019, 74, 111-116.	1.3	54
8	Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension. <i>Circulation</i> , 2019, 139, 2098-2109.	1.6	73
9	Barriers to blood pressure control initiatives: Regional diversity, inadequate measurement techniques, guideline inconsistencies, and health disparities. <i>Journal of Clinical Hypertension</i> , 2019, 21, 204-207.	1.0	0
10	Response to "A Short Insight on Two Different Aspects of Arterial Stiffness, Moving Forward or Backward?". <i>American Journal of Hypertension</i> , 2017, 30, e3-e4.	1.0	0
11	Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice. <i>Journal of Clinical Hypertension</i> , 2017, 19, 143-150.	1.0	7
12	Controversies in hypertension: is lower blood pressure always better?. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 618-620.	2.3	2
13	Renal denervation for human hypertension: is there a future?. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 390-392.	2.3	0
14	Arterial Stiffness: Going a Step Beyond. <i>American Journal of Hypertension</i> , 2016, 29, 1223-1233.	1.0	68
15	Age should not be a primary consideration in the management of hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 12-15.	2.3	0
16	Should age determine hypertension management? Recommendations from current guidelines. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 7-9.	2.3	1
17	Response to "Central Blood Pressure Physiology" (More) Critical Review (Schultz et al.). <i>American Journal of Hypertension</i> , 2015, 28, 692-692.	1.0	1
18	Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 526-535.	2.3	13

#	ARTICLE	IF	CITATIONS
19	Brachial vs. Central Systolic Pressure and Pulse Wave Transmission Indicators: A Critical Analysis. American Journal of Hypertension, 2014, 27, 1433-1442.	1.0	38
20	Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress. Journal of the American Society of Hypertension, 2012, 6, 117-123.	2.3	13
21	Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril. Journal of the American Society of Hypertension, 2012, 6, 399-404.	2.3	8
22	Hypertension in diverse populations: a New York State Medicaid clinical guidance document. Journal of the American Society of Hypertension, 2011, 5, 208-229.	2.3	21
23	Value of Angiotensin Receptor Blocker Therapy in Diabetes. Journal of Clinical Hypertension, 2011, 13, 290-295.	1.0	6
24	Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues. Therapeutic Advances in Cardiovascular Disease, 2011, 5, 169-178.	1.0	2
25	Benefits of antihypertensive drugs when blood pressure is below 140/90 mmHg. , 2011, 121, 303-9.		0
26	Are There Benefits of Antihypertensive Therapy Beyond Blood Pressure Lowering?. Current Hypertension Reports, 2010, 12, 440-447.	1.5	5
27	Titration of HCTZ to 50 mg Daily in Individuals With Stage 2 Systolic Hypertension Pretreated With an Angiotensin Receptor Blocker. Journal of Clinical Hypertension, 2007, 9, 45-48.	1.0	15
28	Efficacy and Safety of Treating Stage 2 Systolic Hypertension With Olmesartan and Olmesartan/HCTZ: Results of an Open-Label Titration Study. Journal of Clinical Hypertension, 2007, 9, 36-44.	1.0	40
29	Prehypertension: Demographics, pathophysiology, and treatment. Current Hypertension Reports, 2007, 9, 264-268.	1.5	15
30	Is Postural Adaptation Impaired by Hardened Arteries?. The American Journal of Geriatric Cardiology, 2005, 14, 262-264.	0.7	0
31	Your Drug, My Drug, or Our Drugs: How Aggressive Should We Be With Antihypertensive Therapy?. Journal of Clinical Hypertension, 2005, 7, 5-7.	1.0	3
32	Pulse contour analysis and augmentation index: It's time to move beyond cuff blood pressure measurement. American Journal of Hypertension, 2005, 18, 1-2.	1.0	13
33	Calcium channel blockers in hypertension. Is there still a controversy?. Aging Clinical and Experimental Research, 2005, 17, 1-5.	1.4	0
34	Antihypertensive Efficacy of Candesartan-Lisinopril in Combination vs. Up-Titration of Lisinopril: The AMAZE Trials. Journal of Clinical Hypertension, 2004, 6, 485-493.	1.0	28
35	Arterial stiffness and the systolic hypertension syndrome. Current Opinion in Cardiology, 2004, 19, 341-352.	0.8	135
36	Hypertension in the Metabolic Syndrome and Diabetes: Pathogenesis, Clinical Studies, and Treatment. Journal of Clinical Hypertension, 2003, 5, 3-10.	1.0	9

#	ARTICLE	IF	CITATIONS
37	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>. JAMA - Journal of the American Medical Association, 2003, 289, 2560.	3.8	18,097
38	Determinants of Elevated Pulse Pressure in Middle-Aged and Older Subjects With Uncomplicated Systolic Hypertension. Circulation, 2003, 108, 1592-1598.	1.6	286
39	Omapatrilat Reduces Pulse Pressure and Proximal Aortic Stiffness in Patients With Systolic Hypertension. Circulation, 2002, 105, 2955-2961.	1.6	210
40	Clinical Impact of Renin-Angiotensin System Blockade: Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Antagonists. Journal of Clinical Hypertension, 2002, 4, 11-31.	1.0	5
41	Improved Medical Records Improve Hypertension Management: A Wake Up Call to Payers and Providers. Journal of Clinical Hypertension, 2002, 4, 413-414.	1.0	1
42	Pet Ownership, but Not ACE Inhibitor Therapy, Blunts Home Blood Pressure Responses to Mental Stress. Hypertension, 2001, 38, 815-820.	1.3	263
43	Diameter, pressure and compliance relationships in dorsal hand veins. Vascular Medicine, 2001, 6, 97-102.	0.8	7
44	Importance of Systolic Blood Pressure in Older Americans. Hypertension, 2000, 35, 1021-1024.	1.3	363
45	Heparin attenuates norepinephrine-induced venoconstriction. Vascular Medicine, 1998, 3, 95-100.	0.8	11